Clinical trials: Hyperlipoproteinemia
ASCVD, Elevated Cholesterol
Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C
The purpose of this extension study was to evaluate the efficacy, safety, and tolerability of long-term dosing of Inclisiran. The study was a global multicenter study.
- Conditions
- ASCVD, Elevated Cholesterol, Heterozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia
- Trial name
- ORION-8 (NCT03814187)
- Testing
- Inclisiran Sodium
- Where
- 238 sites in United States, Canada and 11 more
- Volunteers
- 3,275 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Hyperlipidemia
Clinical Trial to Compare the Safety and Pharmacokinetics of YHP1604 in Comparison to the Co-administration of Telmisartan/Amlodipine and Rosuvastatin
This is a phase 1, open label, single-dose, crossover study to investigate the pharmacokinetics of YHP1604 in comparison to the co-administration of telmisartan/amlodipine and rosuvastatin in healthy male volunteers Hypothesis…
- Trial name
- NCT03116516
- Testing
- Temisartan/Amlodipine+Rosuvastatin, YHP1604
- Where
- South Korea
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Yuhan Corporation
Hyperlipidemia, NAFLD
Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
This study will investigate the efficacy, safety, and tolerability of VK2809 in lowering LDL-C and liver fat content in patients with primary hypercholesterolemia and fatty liver disease.
- Trial name
- NCT02927184
- Testing
- VK2809
- Where
- 19 sites in United States
- Volunteers
- 59 people
- Sponsor
- Viking Therapeutics, Inc.
Glycemia, Hypertension
Effect of PATient Education Related to CV Risk factOrs in Type 2 Diabetes Mellitus(Patrol).
This study will address the proportion of achievement patients in treatment target goal on glycemic control, hypertension and hyperlipidemia according to ADA 2008 guideline, among outpatients coming to the Korean primary care…
- Conditions
- Glycemia, Hypertension, Hyperlipidemia
- Trial name
- PATROL (NCT00891124)
- Where
- 7 sites in South Korea
- Volunteers
- 4,045 people
- Sponsor
- AstraZeneca
Diabetes Mellitus
Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients With Progressive Renal Disease
The purpose of this study is to evaluate the effects of Crestor (rosuvastatin) and (Lipitor) atorvastatin on urinary protein excretion over 1 year in patients with Type 1 or 2 diabetes with moderate proteinuria and…
- Trial name
- PLANET 1 (NCT00296374)
- Testing
- Rosuvastatin, Atorvastatin
- Where
- 116 sites in United States, Argentina and 9 more
- Volunteers
- 353 people
- Sponsor
- AstraZeneca
LDL Hyperlipoproteinemia, Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia
Evaluating the Impact of Omega-3 Fatty Acid Supplementation (Soloways™) on Lipid Profiles in Adults With PPARG Polymorphisms
In this study, 102 patients will be evenly randomized into two groups: one set to receive omega-3 fatty acids and the other a placebo.
- Conditions
- LDL Hyperlipoproteinemia, Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia, Triglyceride Storage Type I or II Disease
- Trial name
- SOLIPARG (NCT06154408)
- Testing
- omega-3 fatty acids
- Where
- Russia
- Volunteers
- 102 people
- Sponsor
- S.LAB (SOLOWAYS)
Hypercholesterolaemia, Familial Hypercholesterolaemia
An Observational Study to Evaluate Treatment Patterns in High, Very High and Extreme Cardiovascular Risk Patients With Hypercholesterolemia, Including Familial Hypercholesterolemia
TRAP-HC is a multicenter, observational, longitudinal, prospective study designed to evaluate real-world treatment patterns and lipid-lowering therapy (LLT) management in patients with hypercholesterolemia, including familial…
- Conditions
- Hypercholesterolaemia, Familial Hypercholesterolaemia, CVD Risk
- Trial name
- TRAP-HC (NCT07606118)
- Volunteers
- 2,500 people
- Sponsor
- Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)
Primary Dyslipidemia, Mixed Dyslipidemia
Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia
Randomized, double-blind, double-dummy, 12-week, active-controlled study of pitavastatin 4 mg daily(QD) vs. pravastatin 40 mg daily(QD) in subjects with primary hyperlipidemia or mixed dyslipidemia.
- Trial name
- PREVAIL-US (NCT01256476)
- Testing
- pitavastatin, pravastatin
- Where
- 44 sites in United States
- Volunteers
- 328 people
- Sponsor
- Kowa Research Institute, Inc.
Hypercholesterolemia, Hyperlipidemia
A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia (MK-0859-011)(COMPLETED)
This is a study to assess the safety, efficacy, and tolerability of MK0859 in patients with primary hypercholesterolemia (large amounts of cholesterol in the blood) or mixed hyperlipidemia (high levels of LDL cholesterol…
- Trial name
- NCT00565292
- Testing
- MK0859
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesterolemia
Study of MB07811 in Subjects With Hypercholesterolemia
A Phase 2 randomized, placebo controlled study assessing the efficacy, safety, and tolerability of MB07811 given orally to subjects with primary hypercholesterolemia for 12 weeks followed by a 6-week off drug phase.
- Trial name
- NCT00879112
- Testing
- MB07811
- Where
- 11 sites in United States
- Volunteers
- 80 people
- Sponsor
- Ligand Pharmaceuticals
Obesity, Hyperlipidemia
Body Worlds 3 Nutrition Display
Primary Aim # 1: Determine the willingness of the public to participate in an intervention trial - NutritionQuest's Alive!TM - available in a public forum.
- Trial name
- NCT00669500
- Testing
- Lifestyle intervention
- Where
- United States
- Volunteers
- 3,188 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Ketosis, Metabolic
Effect of Diet Induced Ketosis on LDL Turnover Rates
There have been concerning case reports of marked elevations of LDL-c in some individuals consuming a KD and Dr. Lewis has been referred a number of these cases to his lipid clinic, some of whom have had extreme elevations of LDL…
- Trial name
- NCT05103761
- Testing
- Study diet, Low glycemic index treatment diet
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Atherosclerosis, Leukocyte Activation Disorder
Inflammatory Aspects of Glucose in Hyperlipidemia and Diabetes
In this study, we will investigate both inflammatory systems in healthy volunteers and patients with T2DM on insulin therapy and hyperlipidemia (both familial hyperlipidemia (FH) and familial combined hyperlipidemia (FCH)) during…
- Conditions
- Atherosclerosis, Leukocyte Activation Disorder, Type 2 Diabetes Mellitus, Familial Combined Hyperlipidemia
- Trial name
- INFORM (NCT02130505)
- Testing
- OGTT
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Sint Franciscus Gasthuis
HIV Infections, Hyperlipidemia
Antihyperlipidemic Effects of Oyster Mushrooms
The primary goal of this study is to evaluate the short-term safety and potential efficacy of oyster mushrooms (Pleurotus ostreatus) for treatment of hyperlipidemia in HIV-infected patients who are taking Kaletra, a protease…
- Trial name
- NCT00069524
- Testing
- oyster mushroom
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Center for Complementary and Integrative Health (NCCIH)
Hypercholesterolemia, Familial
Screening for Familial Hypercholesterolemia in Children
Familial hypercholesterolemia is the most common treatable genetic disorder for which a simple, effective treatment is available, with few side effects.
- Trial name
- HYPERCHOF (NCT06555120)
- Testing
- blood sample
- Where
- France
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Homozygous Familial Hypercholesterolemia
A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)
This multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of zodasiran subcutaneous (SC) injection in subjects 12 years of age and older with genetically or clinically diagnosed Homozygous…
- Trial name
- NCT07037771
- Testing
- zodasiran Injection
- Where
- 43 sites in United States, Australia and 16 more
- Volunteers
- 70 people
- Sponsor
- Arrowhead Pharmaceuticals
Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease
A Study of VERVE-101 in Patients With Familial Hypercholesterolemia and Cardiovascular Disease
VT-1001 is an open-label, phase 1b, single-ascending dose study that will evaluate the safety of VERVE-101 administered to patients with heterozygous familial hypercholesterolemia (HeFH), atherosclerotic cardiovascular disease…
- Conditions
- Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Hypercholesterolemia
- Trial name
- NCT05398029
- Testing
- VERVE-101
- Where
- 3 sites in New Zealand, United Kingdom
- Volunteers
- 13 people
- Sponsor
- Verve Therapeutics, Inc.
Hypercholesterolemia
Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment
To evaluate the efficacy of subcutaneous (SC) evolocumab, compared to regularly scheduled low-density lipoprotein cholesterol (LDL-C) apheresis, on reducing the need for future apheresis.
- Trial name
- NCT02585895
- Testing
- Evolocumab, Low-density Lipoprotein Cholesterol (LDL-C) Apheresis
- Where
- 17 sites in United States, Australia and 6 more
- Volunteers
- 39 people
- Sponsor
- Amgen
Hypertension, Depression
Patient-Centred Innovations for Persons With Multimorbidity - Quebec
The aim of Patient-Centred Innovations for Persons With Multimorbidity (PACE in MM) study is to reorient the health care system from a single disease focus to a multimorbidity focus; centre on not only disease but also the…
- Conditions
- Hypertension, Depression, Anxiety, Musculoskeletal Pain
- Trial name
- PACEinMM-QC (NCT02789800)
- Testing
- DIMAC02
- Where
- 2 sites in Canada
- Volunteers
- 284 people
- Sponsor
- Université de Sherbrooke
Hyperlipidemias
To Explore the Treatment Effect of Various Commercially Available Statins on Patients With Hyperlipidemia
The primary objective is to survey the efficacy of various commercially available statins (a class of lipid-lowering agents, for example, rosuvastatin, atorvastatin, simvastatin, lovastatin, pravastatin and fluvastatin) under…
- Trial name
- NCT00726362
- Where
- 8 sites in Taiwan
- Volunteers
- 3,270 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.